Malignant mesothelioma treated with immune checkpoint inhibitors 
with or without cancer vaccine (the NIPU-study)
 Updates

09.01.2023
The trial has completed accrual and randomised 118 patients.

15.11.2022
A total of 109 patients are included in the trial. Only 9 patients remain to be included before completion of 118 patients.

30.11.2021
Rigshospitalet, Copenhagen, Denmark,  has been initiated as study site

01.09.2021
Val d’Hebron, Barcelona, Spain, has been initiated as study site

31.05.2021
Publication on the NIPU-trial in Journal of Translational Medicine

17.12.2020
Karolinska Institutet, Stockholm, Sweden, has been initiated as study site

17.11.2020
Aalborg University Hospital, Ålborg, Denmark, has been initiated as study site

29.10.2020
University of Western Australia, Perth, is now initiated as a sight and will shortly start inclusion of patients


24.09.2020
Oslo University Hospital started inclusion in May 2020. Other sites are expected to start inclusion in November 2020. 

 
Page visits: 520